According to our new research study on "Osteoporosis Treatment Market Forecast to 2031 - Global Analysis - by Drug Class, Type, Route of Administration, Distribution Channel, and Geography," the market is anticipated to grow from US$ 16.83 billion in 2023 and is projected to reach US$ 22.72 billion by 2031; it is expected to register a CAGR of 3.8% during 2023-2031.

Market growth is attributed to the increasing cases of osteoporosis due to modifications in lifestyle and growing awareness and diagnosis of osteoporosis. Growing digital health solutions are likely to offer opportunities for the market growth. However, the comorbidities and complexity associated with osteoporosis treatment hinder the market growth.

The osteoporosis treatment market includes various drugs and therapeutic modalities carefully developed to combat osteoporosis, a disease characterized by bones becoming brittle and prone to fractures. As osteoporosis is a progressive disease, initiating the treatment at an early stage can yield better results. Osteoporosis treatment involves a series of bone density tests to determine the mineral proportion in the bones. Depending on the severity of cases, osteoporosis treatment is suggested to help reduce pain, improve mobility, and reduce the risk of disability. The osteoporosis treatment market growth is driven by growing elderly population, particularly in developed regions, and increasing recognition of osteoporosis as a pressing health issue. Relentless research and development efforts are being made to introduce breakthrough and more effective interventions to treat this debilitating disease. The osteoporosis treatment market report emphasizes the key factors impacting the market and showcases the developments of prominent players.

North America accounted for a major share of the global osteoporosis treatment market in 2023. The North America osteoporosis treatment market is segmented into the US, Canada, and Mexico. The key factors driving the market growth in this region are the aging population with greater awareness of osteoporosis, advanced healthcare infrastructure, and comprehensive access to medical services enable timely diagnosis and treatment. In addition, the presence of large pharmaceutical companies and ongoing research and development initiatives are encouraging the introduction of innovative therapies. Lastly, favorable reimbursement policies and insurance coverage support patients seeking osteoporosis treatment support the market growth in North America.

Growing Digital Health Solutions to Provide Market Opportunities in Future

Digital health solutions provide a platform for more holistic and patient-centered care, enabling healthcare providers to monitor bone health and medication adherence remotely. These solutions include telemedicine, wearable devices, and remote monitoring. Digital health solutions increase patient engagement, facilitate real-time monitoring, and improve adherence to treatment plans. Timely reminders to patients, provision of educational resources, and streamlined communication with healthcare professionals together help in improving treatment plan adherence. Telemedicine facilitates access to specialized care, especially in undeveloped areas, thereby broadening osteoporosis treatment horizons.

The Fracture Risk Assessment Tool App (FRAX App), developed by the Center for Metabolic Bone Diseases at the University of Sheffield, UK, is a user-friendly app for calculating an individual patient's 10-year probability of a major osteoporotic event (clinical spinal, forearm, hip or shoulder fracture) and probability of osteoporotic hip fracture by entering simple clinical and demographic details. For clinicians, the app offers PIN protection for saving assessments, patient results management features (save, delete, and sort options), and email-sharing functionality for patient assessments (responses and results). My Osteoporosis Journey is an app for women newly diagnosed with asymptomatic osteoporosis. The app aims to support patients with treatment through decision-making and self-management and is used as a complement to primary and secondary healthcare workers. The app also helps reduce anxiety and give patients more confidence and a sense of security. The Hip Fracture Risk Calculator app calculates the risk of hip fracture and in-hospital mortality after a hip fracture based on patient demographics and comorbidities. My Osteoporosis Manager @Point of Care is a management tool that allows patients with osteoporosis to track and store relevant health information between doctor visits. It includes the ability to record detailed health information in a digital journal, manage medications and treatments, track bone-specific symptoms and side effects, easy-to-understand charts that record test results and medication adherence, access to patient education materials, and share information with the patient's healthcare provider.

The development and implementation of digital technologies is increasing rapidly. Healthcare departments are committed to collaborating with academics, industry, and the commercial sector to deliver trusted digital solutions that improve patient care. Digital health tools that include reminders, risk assessment, or education can reduce secondary fracture rates, improve bone mineral density testing, and initiate osteoporosis therapy. Leveraging these digital tools improves patient outcomes and opens up innovative opportunities for creating data-driven, personalized treatment strategies and developing integrated care models in the osteoporosis treatment market.

Drug Class -Based Insights

Based on drug class, the osteoporosis treatment market is divided into RANKL, bisphosphonates, selective estrogen receptor modulators (SERM), hormone therapies, and others. The RANKL segment held the largest osteoporosis treatment market share in 2023. However, the hormone therapies segment is predicted to register the highest CAGR during 2021-2031.

Type -Based Insights

The market, based on type, is divided into primary osteoporosis and secondary osteoporosis. The primary osteoporosis segment held a larger market share in 2023 and is estimated to record a faster CAGR during 2023-2031. Primary osteoporosis occurs with aging, which results in slow bone renewal. Primary osteoporosis includes idiopathic osteoporosis, which occurs in children and young adults with unknown etiopathogenesis. Secondary osteoporosis occurs due to secondary factors such as an underlying health condition (gastrointestinal diseases, rheumatological diseases, and chronic kidney diseases) or certain medications (prednisone, hydrocortisone, and dexamethasone).

End User -Based Insights

Based on end user, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest osteoporosis treatment market share in 2023 and is estimated to register the highest CAGR during 2023-2031. Hospital pharmacies hold a significant share of the osteoporosis treatment market, primarily due to their role in acute care and patient management. They play a key role in ensuring the availability of required medication for patients undergoing inpatient treatment, which is often necessary for severe osteoporosis or after fractures. Hospital pharmacies also provide a central location for comprehensive pharmaceutical services, including medication administration, patient education, and monitoring.

Osteoporosis Treatment Market: Competitive Landscape and Key Developments

Pfizer Inc.; Amgen Inc.; Cadila Pharmaceuticals; Eli Lilly and Company; Daiichi Sankyo Company, Limited; Teva Pharmaceuticals Inc.; Asahi Kasei Corporation; Novartis AG; Chugai Pharmaceutical Co., Ltd.; and Teijin Pharma Limited are among the key companies operating in the osteoporosis treatment market.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the osteoporosis treatment market report.